A clinical outcomes and cost analysis comparing photoselective vaporization of the prostate to alternative minimally invasive therapies and transurethral prostate resection for the treatment of benign prostatic hyperplasia.

PURPOSE: We critically evaluated the clinical outcomes and cost characteristics of alternative procedural treatment options for symptomatic benign prostatic hyperplasia. MATERIALS AND METHODS: An outcomes and cost analysis was performed for benign prostatic hyperplasia treatments, including photose...

Full description

Bibliographic Details
Main Authors: Stovsky, MD, Griffiths, R, Duff, S
Format: Journal article
Language:English
Published: 2006
_version_ 1797096709137891328
author Stovsky, MD
Griffiths, R
Duff, S
author_facet Stovsky, MD
Griffiths, R
Duff, S
author_sort Stovsky, MD
collection OXFORD
description PURPOSE: We critically evaluated the clinical outcomes and cost characteristics of alternative procedural treatment options for symptomatic benign prostatic hyperplasia. MATERIALS AND METHODS: An outcomes and cost analysis was performed for benign prostatic hyperplasia treatments, including photoselective vaporization, microwave thermotherapy, transurethral needle ablation, interstitial laser coagulation and transurethral resection. Clinical outcomes were measured by the percent improvement in American Urological Association/International Prostate Symptom Score, the maximum uroflowmetry rate and quality of life score. An economic simulation model was constructed to estimate the expected cost of benign prostatic hyperplasia procedural therapies from a payer perspective. The model included costs of initial treatment, followup care, adverse events and re-treatment. Sensitivity and threshold analyses tested the impact of changing model inputs on base case results. RESULTS: Ablative therapies showed better improvement in symptom score, flow rate and quality of life score compared to thermotherapy procedures. Photoselective vaporization resulted in the largest beneficial changes in American Urological Association/International Prostate Symptom Score, the maximum uroflowmetry rate and the quality of life score at all time points evaluated, followed by transurethral resection and then interstitial laser coagulation. The estimated cost was lower for photoselective vaporization than for any other procedural option at any interval studied. Sensitivity analyses indicated that the results of baseline analyses were robust to reasonable changes in clinical and economic inputs to the model. CONCLUSIONS: Compared to alternative treatment options photoselective vaporization of the prostate is a clinically efficacious and cost-effective treatment for symptomatic benign prostatic hyperplasia.
first_indexed 2024-03-07T04:45:24Z
format Journal article
id oxford-uuid:d311759b-59c7-44b1-b7eb-77453096c901
institution University of Oxford
language English
last_indexed 2024-03-07T04:45:24Z
publishDate 2006
record_format dspace
spelling oxford-uuid:d311759b-59c7-44b1-b7eb-77453096c9012022-03-27T08:08:46ZA clinical outcomes and cost analysis comparing photoselective vaporization of the prostate to alternative minimally invasive therapies and transurethral prostate resection for the treatment of benign prostatic hyperplasia.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:d311759b-59c7-44b1-b7eb-77453096c901EnglishSymplectic Elements at Oxford2006Stovsky, MDGriffiths, RDuff, S PURPOSE: We critically evaluated the clinical outcomes and cost characteristics of alternative procedural treatment options for symptomatic benign prostatic hyperplasia. MATERIALS AND METHODS: An outcomes and cost analysis was performed for benign prostatic hyperplasia treatments, including photoselective vaporization, microwave thermotherapy, transurethral needle ablation, interstitial laser coagulation and transurethral resection. Clinical outcomes were measured by the percent improvement in American Urological Association/International Prostate Symptom Score, the maximum uroflowmetry rate and quality of life score. An economic simulation model was constructed to estimate the expected cost of benign prostatic hyperplasia procedural therapies from a payer perspective. The model included costs of initial treatment, followup care, adverse events and re-treatment. Sensitivity and threshold analyses tested the impact of changing model inputs on base case results. RESULTS: Ablative therapies showed better improvement in symptom score, flow rate and quality of life score compared to thermotherapy procedures. Photoselective vaporization resulted in the largest beneficial changes in American Urological Association/International Prostate Symptom Score, the maximum uroflowmetry rate and the quality of life score at all time points evaluated, followed by transurethral resection and then interstitial laser coagulation. The estimated cost was lower for photoselective vaporization than for any other procedural option at any interval studied. Sensitivity analyses indicated that the results of baseline analyses were robust to reasonable changes in clinical and economic inputs to the model. CONCLUSIONS: Compared to alternative treatment options photoselective vaporization of the prostate is a clinically efficacious and cost-effective treatment for symptomatic benign prostatic hyperplasia.
spellingShingle Stovsky, MD
Griffiths, R
Duff, S
A clinical outcomes and cost analysis comparing photoselective vaporization of the prostate to alternative minimally invasive therapies and transurethral prostate resection for the treatment of benign prostatic hyperplasia.
title A clinical outcomes and cost analysis comparing photoselective vaporization of the prostate to alternative minimally invasive therapies and transurethral prostate resection for the treatment of benign prostatic hyperplasia.
title_full A clinical outcomes and cost analysis comparing photoselective vaporization of the prostate to alternative minimally invasive therapies and transurethral prostate resection for the treatment of benign prostatic hyperplasia.
title_fullStr A clinical outcomes and cost analysis comparing photoselective vaporization of the prostate to alternative minimally invasive therapies and transurethral prostate resection for the treatment of benign prostatic hyperplasia.
title_full_unstemmed A clinical outcomes and cost analysis comparing photoselective vaporization of the prostate to alternative minimally invasive therapies and transurethral prostate resection for the treatment of benign prostatic hyperplasia.
title_short A clinical outcomes and cost analysis comparing photoselective vaporization of the prostate to alternative minimally invasive therapies and transurethral prostate resection for the treatment of benign prostatic hyperplasia.
title_sort clinical outcomes and cost analysis comparing photoselective vaporization of the prostate to alternative minimally invasive therapies and transurethral prostate resection for the treatment of benign prostatic hyperplasia
work_keys_str_mv AT stovskymd aclinicaloutcomesandcostanalysiscomparingphotoselectivevaporizationoftheprostatetoalternativeminimallyinvasivetherapiesandtransurethralprostateresectionforthetreatmentofbenignprostatichyperplasia
AT griffithsr aclinicaloutcomesandcostanalysiscomparingphotoselectivevaporizationoftheprostatetoalternativeminimallyinvasivetherapiesandtransurethralprostateresectionforthetreatmentofbenignprostatichyperplasia
AT duffs aclinicaloutcomesandcostanalysiscomparingphotoselectivevaporizationoftheprostatetoalternativeminimallyinvasivetherapiesandtransurethralprostateresectionforthetreatmentofbenignprostatichyperplasia
AT stovskymd clinicaloutcomesandcostanalysiscomparingphotoselectivevaporizationoftheprostatetoalternativeminimallyinvasivetherapiesandtransurethralprostateresectionforthetreatmentofbenignprostatichyperplasia
AT griffithsr clinicaloutcomesandcostanalysiscomparingphotoselectivevaporizationoftheprostatetoalternativeminimallyinvasivetherapiesandtransurethralprostateresectionforthetreatmentofbenignprostatichyperplasia
AT duffs clinicaloutcomesandcostanalysiscomparingphotoselectivevaporizationoftheprostatetoalternativeminimallyinvasivetherapiesandtransurethralprostateresectionforthetreatmentofbenignprostatichyperplasia